Senti Biosciences Holdings, Inc. — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Senti Biosciences Holdings, Inc. closed its merger with Celadon Partners SPV 35 (Parent) on October 21, 2026. As part of the deal, the company issued Contingent Value Rights (CVRs) with aggregate payment cap of $60M tied to three milestones for SENTI-202: BLA filing ($10M), FDA approval ($20M), and $200M+ cumulative Net Sales ($30M). The company granted Celadon a $2.5M equity investment at minimum Nasdaq price and signed IP and consulting agreements with Opco (former operating subsidiary) for transitional support through a 12-month term renewable for 12 months.
Why this rating
CVR structure is common post-merger; consulting/IP transition routine. $60M cap is ~113% of $53.2M company size, but entirely contingent on future drug development—not cash outlay now. No imminent business disruption evident from filed documents.
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.